Advertisement
open access
Medical Conferences
Conference Reports
Conference Proceedings
Disease Areas
Medical News
Multimedia
Podcast Channel
Videos
Webinar
About
2024 Medicom Conference Planning
Conference Proceedings
Home
>
Dermatology
>
EADV 2022
EADV 2022
European Academy of Dermatology and Venereology
07
–
10 September 2022 Milan, Italy
Table of Contents
Colophon
Table of Contents
Featured articles
Letter from the Editor
Editor
Prof. Peter CM van de Kerkhof, Radboud University Nijmegen Medical Centre, the Netherlands
EADV 2022 Highlights Podcast
Presented By
Dr Rachel Giles, Medicom
Psoriasis and Psoriatic Arthritis: What You Need to Know
Novel oral psoriasis drug maintains efficacy over 2 years
Presented By
Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA
A3 adenosine receptor agonist showed modest efficacy but excellent tolerability
Presented By
Dr Kim A. Papp, Probity Medical Research, Canada
Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA
Presented By
Dr Kim Papp, Probity Medical Research, Canada
AI machine learning algorithm useful in early detection of PsA
Presented By
Dr Jonathan Shapiro, Maccabi Healthcare Services, Israel
Novel Developments in Sun Protection
Myths regarding “health benefit” of suntan prevail in majority of population
Presented By
Prof. Thierry Passeron, Université Côte d’Azur, France
Fern extract reverses severe actinic keratosis lesions
Presented By
Dr Stefania Guida, Sapienza University of Rome, Italy
Vitiligo in 2022
Enhancing re-pigmentation rates with topical ruxolitinib in all body areas
Presented By
Prof. Thierry Passeron, University Côte d’Azur, France
Markedly lower skin cancer risk in vitiligo patients
Presented By
Dr John Ferguson, St John’s Institute of Dermatology, UK
Pruritus Treatment: Novel Agents Entering the Arena
Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis
Presented By
Prof. Gil Yosipovitch, University of Miami, FL, USA
Nalbuphine: aspiring to become another treatment for prurigo nodularis?
Presented By
Prof. Sonja Ständer, University Medical Centre of Münster, Germany
Notalgia paresthetica: may κ-opioid receptor agonists be a long-awaited effective therapy?
Presented By
Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA
Pharmacotherapy in Hidradenitis Suppurativa: New Opportunities
High potential for secukinumab as next biologic treatment for HS
Presented By
Prof. Alexandra Kimball, Harvard Medical School, MA, USA
Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise
Presented By
Prof. Alexandra Kimball, Harvard Medical School, MA, USA
Best of the Posters
High rate of non- or partial responders jeopardises therapeutic success in HS
Presented By
Dr Hayley Wallinger, Adelphi Real World, UK
Genital psoriasis: high prevalence, often underdiagnosed
Presented By
Dr Toni Klein, University Medical Center Hamburg-Eppendorf, Germany
Decreased overall survival in melanoma patients with low vitamin D
Presented By
Dr Inés Gracia-Darder, Son Espases University Hospital, Spain
News in Atopic and Seborrheic Dermatitis
Baricitinib possible therapeutic option for children with AD
Presented By
Dr Antonio Torrelo Fernández, Hospital Infantil Universitario Niño Jesús, Spain
Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients
Presented By
Dr Stephan Weidinger, University Hospital Schleswig-Holstein, Germany
IL-13 inhibition with lebrikizumab shows high maintenance rates in AD
Presented By
Prof. Andrew Blauvelt, Oregon Medical Research Center, OR, USA
Does 8 weeks of emollients use prevent AD in high-risk infants?
Presented By
Prof. Alan Irvine, Trinity College Dublin, Ireland
Roflumilast foam led to high response rates in seborrheic dermatitis
Presented By
Prof. Andrew Blauvelt, Oregon Medical Research Center, OR, USA
What Is Hot in Hair Disorders?
Long-term improvement in alopecia areata with ritlecitinib therapy
Presented By
Dr Athanasios Tsianakas, Fachklinik Bad Bentheim, Germany
Topical gel plus finasteride beneficial for patients with androgenetic alopecia
Presented By
Dr Michela Starace, University of Bologna, Italy
Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata
Presented By
Prof. Brett King, Yale University School of Medicine, CT, USA